Triage Survey for Neurology Research Eligibility
NCT06104852 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2023-10-27
Summary
TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.
Conditions
- Alzheimer Disease
Interventions
- OTHER
-
Survey
Participants will be surveyed on demographics, medical history, and current memory and cognitive concerns. Vitals signs, urine drug screen, blood draw may be collected.
- OTHER
-
Optional Medication Washout
Participants taking memory medications which require a down-taper per the judgment of the study physicians may participate in a medication washout period during study screening.
Sponsors & Collaborators
-
Adams Clinical
lead NETWORK
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-06-02
- Primary Completion
- 2027-06-02
- Completion
- 2027-06-02
Countries
- United States
Study Locations
More Related Trials
-
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
NCT03538522 ·Status: COMPLETED ·Phase: PHASE2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
NCT04931459 ·Status: COMPLETED ·Phase: PHASE1
-
Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
NCT04749563 ·Status: COMPLETED ·Phase: PHASE1
-
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
NCT01023685 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
NCT05225415 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
NCT01998841 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
NCT05108922 ·Status: COMPLETED ·Phase: PHASE3
-
Alzheimer's Tau Platform: Regimen A - AADvac1
NCT07167966 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
NCT04445831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
NCT07158905 ·Status: RECRUITING ·Phase: PHASE1
-
Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
NCT00955422 ·Status: COMPLETED
-
Reversal of Cognitive Decline (ReCODE) Study
NCT03883633 ·Status: COMPLETED
-
Gene Therapy for Alzheimer's Disease Clinical Trial
NCT00017940 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of NH280105 in Healthy Adult Participants
NCT06870058 ·Status: COMPLETED ·Phase: PHASE1
-
Multicenter Trial of Prednisone in Alzheimer's Disease
NCT00000178 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
NCT02353598 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
NCT01350362 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
NCT00777608 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance
NCT01194336 ·Status: COMPLETED